awmsg logo



efavirenz (Sustiva®)


Reference No. 2666

Publication date:
11/01/2016


Appraisal information

efavirenz (Sustiva®) 50 mg capsule
efavirenz (Sustiva®) 100 mg capsule
efavirenz (Sustiva®) 200 mg capsule
efavirenz (Sustiva®) 600 mg film-coated tablet


Company: Bristol-Myers Squibb Pharmaceuticals Ltd
BNF category: Infections
NMG meeting date: 04/11/2015
AWMSG meeting date: 09/12/2015
   
   
Submission Type: Limited Submission
Status: Recommended
Advice No: 4015
Ministerial ratification: 06/01/2016

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Efavirenz (Sustiva®) is recommended as an option for use within NHS Wales in antiviral combination treatment for the treatment of human immunodeficiency virus-1 (HIV-1) infected children 3 months of age to 3 years and weighing at least 3.5kg. Sustiva® has not been adequately studied in patients with advanced HIV disease, namely patients with CD4 counts < 50 cells/mm3, or after failure of protease inhibitor (PI) containing regimens. Although cross-resistance of efavirenz with PIs has not been documented, there are at present insufficient data on the efficacy of subsequent use of PI based combination therapy after failure of regimens containing Sustiva®.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download